pembrolizumab
What Pembrolizumab Is Used For:
- Treatment of recurrent or metastatic cervical cancer in patients whose tumors express PD-L1 (combined positive score [CPS] ≥ 1), as determined by an approved test, and with disease progression on or after chemotherapy.
- Treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy.
- For the treatment of unresectable or metastatic melanoma.
- For the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection
- Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy.
- For treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
- Treatment of primary mediastinal large B-cell lymphoma (PMBCL) in adult or pediatric patients with refractory disease who have relapsed after 2 or more prior lines of therapy.
- For treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
- For treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
- For treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors or colorectal cancer that have progressed following prior treatment.
- For treatment of patients with hepatocellular cancer (HCC) who have been previously treatment with sorafenib.
- For Treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell cancer.
- For first-line treatment plus axitinib of patients with advanced renal cell carcinoma (RCC).
- For treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
- For treatment of patients with advanced esophageal squamous cell cancer whose tumors express PD-L1 as determined by an FDA approved test.
- In combination with the drug lenvatinib for treatment of patients with advanced endometrial cancer.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.